Toremifene

Generic Name
Toremifene
Brand Names
Fareston
Drug Type
Small Molecule
Chemical Formula
C26H28ClNO
CAS Number
89778-26-7
Unique Ingredient Identifier
7NFE54O27T
Background

Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs.
...

Indication

For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.

Associated Conditions
Metastatic Breast Cancer
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

First Posted Date
2023-06-06
Last Posted Date
2024-02-08
Lead Sponsor
Fudan University
Target Recruit Count
766
Registration Number
NCT05891093
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China

🇨🇳

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China

🇨🇳

Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 12 locations

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

First Posted Date
2023-04-06
Last Posted Date
2023-05-18
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
700
Registration Number
NCT05801705
Locations
🇨🇳

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

First Posted Date
2020-12-14
Last Posted Date
2020-12-14
Lead Sponsor
First Hospital of China Medical University
Target Recruit Count
1354
Registration Number
NCT04666805
Locations
🇨🇳

The First Hospital of China Medical University, Shenyang, Liaoning, China

Selective Estrogen Modulation and Melatonin in Early COVID-19

Phase 2
Withdrawn
Conditions
Covid19
Interventions
Other: Placebo
Drug: Toremifene
Drug: Melatonin
First Posted Date
2020-08-28
Last Posted Date
2021-05-10
Lead Sponsor
Reena Mehra, MD
Registration Number
NCT04531748

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Phase 3
Recruiting
Conditions
Breast Cancer Female
Interventions
Drug: Tamoxifen
Drug: Toremifene
First Posted Date
2017-11-22
Last Posted Date
2017-11-22
Lead Sponsor
Chinese Anti-Cancer Association
Target Recruit Count
844
Registration Number
NCT03351062
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Hebei Tumor Hospital, Shijiazhuang, Hebei, China

🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

and more 18 locations

Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer

First Posted Date
2015-07-23
Last Posted Date
2019-09-04
Lead Sponsor
N.N. Petrov National Medical Research Center of Oncology
Target Recruit Count
96
Registration Number
NCT02506790
Locations
🇷🇺

N.N. Petrov Research Institute of Oncology Clinical Diagnostic Department, Saint - Petersburg, Russian Federation

Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets

Phase 2
Conditions
Desmoid Type-fibromatosis
Interventions
Drug: Toremifene
First Posted Date
2015-02-02
Last Posted Date
2015-02-02
Lead Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Target Recruit Count
25
Registration Number
NCT02353429
Locations
🇮🇹

Fondazione IRCCS Istituto Tumori Milano, Milan, Italy

Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer

Phase 4
Completed
Conditions
Breast Cancer
Interventions
Drug: Toremifene
Drug: Tamoxifen
First Posted Date
2015-01-26
Last Posted Date
2019-09-24
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
104
Registration Number
NCT02344940
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

Estradiol-Receptor Blockade in Older Men and Women

First Posted Date
2014-10-22
Last Posted Date
2016-09-14
Lead Sponsor
Mayo Clinic
Target Recruit Count
40
Registration Number
NCT02271282
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

First Posted Date
2014-05-07
Last Posted Date
2014-06-04
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
300
Registration Number
NCT02132390
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy